

Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India.

February 07, 2022

To, The Listing Department, **BSE LIMITED,** Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai- 400 001 To, The Listing Department **National Stock Exchange of India Limited,** Exchange Plaza, 5<sup>th</sup> Floor, Plot no. C-1, G-Block, Bandra Kurla Complex, Mumbai -400051

Scrip Code: 543349

**NSE Symbol: AMIORG** 

## Subject: <u>Unaudited Standalone & Consolidated Financial Results for the Third Quarter & Nine Months</u> ended 31<sup>st</sup> December, 2021

We would like to inform that the Board of Directors at its meeting held on February 07, 2022 inter alia, considered and approved the Unaudited Standalone and consolidated Financial Results for the third quarter and nine months ended December 31, 2021 as recommended by the Audit Committee.

The Board also took note of the 'Limited Review Report' issued by the Company's Statutory Auditors, M/s. Maheshwari & Co. Chartered Accountants. We enclose herewith copy of the Unaudited Financial Results (Standalone and Consolidated) for the third quarter and nine-months ended December 31, 2021 and the said Limited Review Report.

As required under Regulation 47 (1) (b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the extract of the Financial Results will be published in the newspapers in the format prescribed by SEBI. The Financial Results will also be available on the Company's website at <u>www.amiorganics.com</u>

Kindly take above as compliance of Regulation 33 and 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 2.30 P.M. and concluded at 5. 05 P.M.

Thanking you, Yours faithfully, For, AMI ORGANICS LIMITED

## Ella Uumari

Ekta Kumari Srivastava Company Secretary & Compliance Officer

Encl: As above



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to, The Board of Directors Ami Organics Limited

- 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of AMI. ORGANICS LIMITED ('the Company') for the quarter and nine months ended December 31, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted and procedure performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Head Office : 10-11, Third Floor, Esplanade Building, 3, A. K. Naik Marg (Bestian Road), Next to New Empire Cinema, Fort, C.S.T. Mumbai - 400 001. Tel. : +91-22-22077472/22072620 • E-mail : info@maheshwariandco.in • www.maheshwariandco.ir

5. We have not audited or reviewed the comparative financial information appearing in the Statement of the corresponding quarter and nine months ended December 31,2020 which have been prepared solely based on the information compiled by the management and has been approved by the Board of Directors. Further, we report that the figures for the quarter ended December 31, 2021 represent the derived figures between the reviewed figures in respect of the period from April 1, 2021 to December 31, 2021 and the reviewed figures for the half year ended September 30, 2021.

For Maheshwari & Co. **Chartered Accountants** FRN: 105834W

Pawan Gattani Partner Membership No. 144734

UDIN: 22144734AAQPRY8926

Place: Surat Date: February 07, 2022

FRN : 105834W MUMBAI \* ered Acc



AMI ORGANICS LIMITED CIN- L24100GJ2007PLC051093 Plot No. 440/4, 5 & 6, Road No. 82/A, GIDC Sachin, Surat – 394 230 Gujarat, India; Tel: +91 261 239 7193; +91 72279 77744 and +91 75730 15366. E-mail: cs@amiorganics.com; Website: www.amiorganics.com

Statement of Unaudited Standalone Financial Results for the quarter and nine month ended December 31, 2021

	(Rs. In Lakhs, unless otherwise sta Ouarter ended Nine Month Ended Year end					
	Quarter ended			Nine Mor	Year ended	
Particulars	December 31, 2021	September 30, 2021	December 31, 2020	December 31, 2021	December 31, 2020	March 31, 2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.Revenue						
Revenue from operations	14115.32	12,230.83	9,195.32	37,659.14	24,772.31	34,060.79
Other income	139.17	16.34	11.67	258.68	132.89	133.03
Total Revenue (A)	14,254.49	12,247.17	9,206.99	37,917.82	24,905.20	34,193.82
II.Expenses					(m)	
Cost of raw materials consumed	7314.81	6,983.56	4,654.77	20,624.45	13,144.00	17,468,67
Changes in inventories of finished goods/traded goods and		-,	.,		,	
work-in-progress	(174.68)	(1,296.90)	0.85	(1,359.12)	118.22	481.36
Employee benefits expense	1083.95	1,057.80	535.88	3,039.54	1,553.10	2,098.93
Finance costs	33.78	269.17	163.45	581.86	420.55	561.84
Depreciation and amortisation expense	242.31	231.84	99.11	696.85	300.30	418.80
Other expenses	2898.59	2,749.42	1,828.79	7,415.43	4,260.55	5,991.59
Total expenses (B)	11,398.76	9,994.89	7,282.85	30,999.01	19,796.72	27,021.19
I otal expenses (b)	11,398.70	9,994.09	7,202.05	30,999,01	17,790.72	27,021.19
III.Profit before tax (A-B)	2,855.73	2,252.28	1,924.14	6,918.81	5,108.48	7,172.63
IV.Tax expense:						
- Current tax	738.09	434.69	452.71	1,578.71	1,244.55	1,756.40
- Deferred tax	170.63	70.60	25.67	273.57	4.13	16.33
	908.72	505,29	478.38	1,852.28	1,248.68	1,772.73
V.Profit for the period / year	1,947.01	1,746,99	1,445.76	5,066.53	3.859.80	5,399,90
VI.Other Comprehensive Income / (Loss)						
Items that will be reclassified to profit or loss Exchange difference on translation on Foreign Entity	*		*			:=3
Items that will not be reclassified to profit or loss			l II			
Re-measurement gain/ (losses) on defined benefit plans	(6.01)	75.68	(3.26)	145.34	(5.12)	(3.73)
Tax impact of items that will not be reclassified to statement of profit and loss	1.51	(19.04)	0.82	(36.58)	1.29	0.94
VII.Total comprehensive income for the period $\setminus$ year	1,942,51	1,803.63	1,443.32	5,175.29	3,855.97	5,397.11
VIII, Paid up equity share capital	3,643.71	3,643.71	1,050.00	3,643.71	1,050.00	3,150.00
(Face value Rs. 10 per share)	3,073.71	3,073.71	1,030.00	3,013.71	2,050.00	5,150.00
IX. Other Equity						13,245.10
X.Earnings per equity share	1					
Basic EPS (Rs.)	5,69	5,11	4.59	16.08	12.25	17.14
Diluted EPS (Rs.)	5.69	5,11	4.59	16.08	12.25	17.14

For Ami Organics Limited Managing Director





Notes to Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2021

- In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2021 (Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 07, 2022 and have been subjected to a limited review by the Statutory Auditors of the Company.
- 2. The financial results for the quarter and nine months ended December 31, 2020 have not been audited or reviewed by our statutory auditors. However, the management has exercised necessary due diligence to ensure that the financial results for these periods provide a true and fair view of the Company's affairs. Further, the figures for the quarter ended December 20, 2021 are derived figures between the reviewed figures in respect of the period from April 1, 2021 to December 31, 2021 and the reviewed figures for the half year ended September 30, 2021.
- 3. The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS") as prescribed under section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended and SEBI Circular No.CIR/CFD/CMD 1/44/2019 dated March 29, 2019.
- 4. The Company has completed its Initial Public Offering IPO) of 9,338,288 equity shares of face value of Rs.10/-each for cash at an issue price of Rs.610/- per equity share aggregating to Rs. 5,6963.6 lakhs, consisting fresh issue of 3,278,688 equity shares aggregating to Rs. 20,000 lakhs and an offer for sale of 6,059,600 equity shares aggregating to Rs. 3,6963.56 lakhs by the selling shareholders. The equity shares of the Company were listed on BSE Limited and National Stock Exchange of India Limited on September 14, 2021. Accordingly, the Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2021 are drawn up for the first time in accordance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 (the "Listing Requirements"). Company has undertaken a Pre-IPO Placement of Equity Shares aggregating to ₹ 10,000 lakh by issuing fresh 16,58,374 equity shares of face value Rs. 10/- each for cast at an issue price of Rs. 603/- per share. The size of the Fresh Issue has been reduced by ₹ 1,000 million pursuant to the Pre-IPO Placement

The utilisation of IPO proceeds is summarised below:

				(Rs. In Mn)	
Sr No	Item Heads	Projected utilization of proceeds as per the offer document	Amount Utilized upto December 31, 2021	Total unutilized amount as on December 31, 2021	
1	Debt repayment	1,400.00	1,400.00		
2	Working Capital (FY 2021-22)	500.00	430.00	70.00	
3	Working Capital (FY 2022-23)	400.00	0.00	400.00	
4	General Corporate	459.31	56.73	402.58	
5	Issue Expense	240.69	240.69	( <b>=</b> )	
	Total*	3,000.00	3,000.00	872.58	

For Ami Organics Limited Managing Director





Deployment of unutilized proceeds:

Sr. No	Type of instrument where amount invested*	Amount invested (INR in million)	Maturity date	Earnings (INR in million)	Return on Investment (ROI %)	Book Value as at the end of quarter (INR in million)
1	Deposits with Axis	80.00	08/10/2022	4.06	5.1%	80.00
2	Deposits with IndusInd Bank*	732.58	22/11/2022	68.17	4.75%	732.58
3	Balance at Public Issue Account (With Axis Bank)	60.00		. <del></del>	-	60.00

\*Total Investment in multiple FDs with bank, is INR 770 million, where funds from internal accruals are also included.

- 5. The new Code on Social Security, 2020 has been enacted, which would impact the contributions by the Company towards Provident Fund and Gratuity, the effective date from which the changes are applicable is yet to be notified and the rules are yet to be framed, The Company will complete its evaluation and will give appropriate impact in its financial results in the period in which, the Code becomes effective and the related rules are published.
- 6. As the Company operates in a single operating segment, it did not give rise to different operating segments in accordance with Ind AS 108 Operating Segments
- 7. As part of the capacity and production rationalization exercise, Company has transferred the current production operations of speciality chemical business from Ankleshwar facility, which was acquired from Gujarat Organics Limited to one single location at Jhagadia facility. The shifting of speciality chemicals business at single location will help Company achieve better utilization of the plant and improve operational efficiency. There shall be no revenue loss and employee layoffs because of transfer of aforementioned production operation from Ankleshwar to Jhagadia unit of Company. Meanwhile all the current production operations at Company's Surat Sachin unit, and Jhagadia unit are running normal business as usual. Company intends to restructure the Ankleshwar production facility and utilize the same for the expansion of pharma intermediate business to support future growth requirement. The planning, design and engineering for proposed capex at Ankleshwar unit is under, Company has already received Environment Clearance for the proposed restructure of Ankleshwar unit.
- 8. The previous periods numbers have been regrouped/ rearranged wherever necessary to confirm the current period presentation
- 9. The above Unaudited Standalone Financial Results of the Company are available on Company's website <u>www.amiorganics.com</u> and also on the website of BSE (<u>www.bseindia.com</u>) and NSE (www.nseindia.com), where the shares of the Company are listed







Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to, The Board of Directors Ami Organics Limited

- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of AMI ORGANICS LIMITED ('the Holding Company') and its joint venture (the Holding Company and the joint venture are together referred to as the "Group") for the quarter and nine months ended December 31, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the results of the Joint Venture, Ami Onco-Theranostics, LLC
- 5. Based on our review conducted and procedure performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FRN : 105834W MUMBA ed Acc

Head Office : 10-11, Third Floor, Esplanade Building, 3, A. K. Naik Marg (Bestian Road), Next to New Empire Cinema, Fort, C.S.T. Mumbai - 400 001. Tel. : +91-22-22077472/22072620 • E-mail : info@maheshwariandco.in • www.maheshwariandco.in

6. We have not audited or reviewed the comparative financial information appearing in the Statement of the corresponding quarter and nine months ended December 31,2020 which have been prepared solely based on the information compiled by the management and has been approved by the Board of Directors. Further, we report that the figures for the quarter ended December 31, 2021 represent the derived figures between the reviewed figures in respect of the period from April 1, 2021 to December 31, 2021 and the reviewed figures for the half year ended September 30, 2021.

For Maheshwari & Co. **Chartered Accountants** FRN: 105834W

Pawan Gattani Partner Membership No. 144734

UDIN: 22144734AAQQJK8030

Place: Surat Date: February 07, 2022





AMI ORGANICS LIMITED CIN- L24100GJ2007PLC051093

Plot No. 440/4, 5 & 6, Road No. 82/A, GIDC Sachin, Surat – 394 230 Gujarat, India; Tel: +91 261 239 7193; +91 72279 77744 and +91 75730 15366. E-mail: cs@amiorganics.com; Website: www.amiorganics.com

Statement of Unaudited Consolidated Financial Results for the quarter and nine month ended December 31, 2021

	(Rs. In Lakhs, unless o Ouarter ended Nine Month Ended					Year ended	
		Quarter entreu				rear enueu	
Particulars	December 31, 2021	September 30, 2021	December 31, 2020	December 31, 2021	December 31, 2020	March 31, 2021	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
I.Revenue							
Revenue from operations	14115.32	12,230.83	9,195.32	37,659.14	24,772.31	34,060.79	
Other income	139.17	16.34	16.61	258.68	137.82	137.97	
Total Revenue (A)	14,254.49	12,247.17	9,211.93	37,917.82	24,910.13	34,198.76	
II.Expenses							
Cost of raw materials consumed	7314.81	6,983,56	4.654.77	20.624.45	13,144.00	17,468,67	
Changes in inventories of finished goods/traded goods and	7517,01	0,703.30	+,03+.77	20,024.43	13,144.00	17,400.07	
work-in-progress	(174.68)	(1,296.90)	0.85	(1,359.12)	118.22	481.36	
Employee benefits expense	1083.95	1,057.80	535.87	3,039.54	1,554.92	2,100.76	
Finance costs	33.78	269.17	163.45	581.86	420.55	561.84	
Depreciation and amortisation expense	242.31	231.84	99.11	696.85	300.30	418.80	
Other expenses	2898.59	2,749.42	1,833,74	7,415.43	4,263.67	5,994,71	
Total expenses (B)	11,398.76	9,994.88	7,287.79	30,999.01	19,801.66	27,026.14	
Total expenses (b)	11,390,70	9,994.00	7,201.19	30,999,01	19,001.00	27,020.14	
III.Profit before tax (A-B)	2,855.73	2,252.29	1,924.14	6,918.81	5,108.47	7,172.62	
IV.Tax expense:							
- Current tax	738.09	434.69	452.71	1,578.71	1,244.55	1,756.40	
- Deferred tax	170.63	70.60	25.67	273.57	4.13	16.33	
	000 50	505.00	(50.00	4 052 00	1 2 4 0 7 0	4 660 60	
	908.72	505.29	478.38	1,852.28	1,248.68	1,772.73	
V.Profit for the period / year	1,947.01	1,747.00	1,445.76	5,066.53	3,859.79	5,399.89	
VI.Other Comprehensive Income / (Loss)							
Items that will be reclassified to profit or loss				(0.00	(01.17)	(05.40)	
Exchange difference on translation on Foreign Entity	14.92	(7.50)	7.76	62,28	(91.17)	(85,18)	
Items that will not be reclassified to profit or loss							
Re-measurement gain/ (losses) on defined benefit plans	(6.01)	75.68	(3.26)	145.34	(5.12)	(3.73)	
Tax impact of items that will not be reclassified to statement of	(0.01)		()		()	(	
profit and loss	1.51	(19.04)	0.82	(36.58)	1.29	0.94	
	1 055 42	1 706 14	1 451 00	E 227 E7	2 764 70	F 211 02	
VII.Total comprehensive income for the period \ year	1,957.43	1,796.14	1,451.08	5,237.57	3,764.79	5,311.92	
VIII. Paid up equity share capital	3,643.71	3,643.71	1,050.00	3,643.71	1,050.00	3,150.00	
(Face value Rs. 10 per share)		-,				,	
IX. Other Equity						13,543.32	
K.Earnings per equity share							
Basic EPS (Rs.)	5.69	5.11	4.59	16.08	12.25	17.14	
Diluted EPS (Rs.)	5.69	5.11	4.59	16.08	12.25	17.14	







Notes to Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2021

- In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2021 (Unaudited Consolidated Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 07, 2022 and have been subjected to a limited review by the Statutory Auditors of the Company.
- 2. The financial results for the quarter and nine months ended December 31, 2020 have not been audited or reviewed by our statutory auditors. However, the management has exercised necessary due diligence to ensure that the financial results for these periods provide a true and fair view of the Company's affairs. Further, the figures for the quarter ended December 20, 2021 are derived figures between the reviewed figures in respect of the period from April 1, 2021 to December 31, 2021 and the reviewed figures for the half year ended September 30, 2021.
- 3. The Unaudited Consolidated Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS") as prescribed under section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended and SEBI Circular No.CIR/CFD/CMD 1/44/2019 dated March 29, 2019.
- 4. The Company has completed its Initial Public Offering IPO) of 9,338,288 equity shares of face value of Rs.10/-each for cash at an issue price of Rs.610/- per equity share aggregating to Rs. 5,6963.6 lakhs, consisting fresh issue of 3,278,688 equity shares aggregating to Rs. 20,000 lakhs and an offer for sale of 6,059,600 equity shares aggregating to Rs. 3,6963.56 lakhs by the selling shareholders. The equity shares of the Company were listed on BSE Limited and National Stock Exchange of India Limited on September 14, 2021. Accordingly, the Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2021 are drawn up for the first time in accordance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 (the "Listing Requirements"). Company has undertaken a Pre-IPO Placement of Equity Shares aggregating to ₹ 10,000 lakh by issuing fresh 16,58,374 equity shares of face value Rs. 10/-each for cast at an issue price of Rs. 603/- per share. The size of the Fresh Issue has been reduced by ₹ 1,000 million pursuant to the Pre-IPO Placement

The utilisation of IPO proceeds is summarised below:

Sr No	Item Heads	Projected utilization of proceeds as per the offer document	Amount Utilized upto December 31, 2021	Total unutilized amount as on December 31, 2021	
1	Debt repayment	1,400.00	1,400.00	: #2	
2	Working Capital (FY 2021-22)	500.00	430.00	70.00	
3	Working Capital (FY 2022-23)	400.00	0.00	400.00	
4	General Corporate	459.31	56.73	402.58	
5	Issue Expense	240.69	240.69		
	Total*	3,000.00	3,000.00	872.58	







(De In Mn)

## Deployment of unutilized proceeds:

Sr. No	Type of instrument where amount invested*	Amount invested (INR in million)	Maturity date	Earnings (INR in million)	Return on Investment (ROI %)	Book Value as at the end of quarter (INR in million)
1	Deposits with Axis	80.00	08/10/2022	4.06	5.1%	80.00
2	Deposits with IndusInd Bank*	732.58	22/11/2022	68.17	4.75%	732.58
3	Balance at Public Issue Account (With Axis Bank)	60.00	×	-	-	60.00

\*Total Investment in multiple FDs with bank, is INR 770 million, where funds from internal accruals are also included.

- 5. The new Code on Social Security, 2020 has been enacted, which would impact the contributions by the Company towards Provident Fund and Gratuity, the effective date from which the changes are applicable is yet to be notified and the rules are yet to be framed, The Company will complete its evaluation and will give appropriate impact in its financial results in the period in which, the Code becomes effective and the related rules are published.
- 6. As the Company operates in a single operating segment, it did not give rise to different operating segments in accordance with Ind AS 108 Operating Segments
- 7. As part of the capacity and production rationalization exercise, Company has transferred the current production operations of speciality chemical business from Ankleshwar facility, which was acquired from Gujarat Organics Limited to one single location at Jhagadia facility. The shifting of speciality chemicals business at single location will help Company achieve better utilization of the plant and improve operational efficiency. There shall be no revenue loss and employee layoffs because of transfer of aforementioned production operation from Ankleshwar to Jhagadia unit of Company. Meanwhile all the current production operations at Company's Surat Sachin unit, and Jhagadia unit are running normal business as usual. Company intends to restructure the Ankleshwar production facility and utilize the same for the expansion of pharma intermediate business to support future growth requirement. The planning, design and engineering for proposed capex at Ankleshwar unit is under, Company has already received Environment Clearance for the proposed restructure of Ankleshwar unit.
- 8. The previous periods numbers have been regrouped/ rearranged wherever necessary to confirm the current period presentation
- 9. The above Unaudited Consolidated Financial Results of the Company are available on Company's website <u>www.amiorganics.com</u> and also on the website of BSE (<u>www.bseindia.com</u>) and NSE (www.nseindia.com), where the shares of the Company are listed





